Latest Head and neck cancer Stories
IASIS MEDICAL Sees Substantial Opportunity In Offering IsoRay's Entire Product Line RICHLAND, Wash., May 21, 2013 /PRNewswire/ -- IsoRay, Inc. (AMEX: ISR), (http://www.isoray.com/), announced today that it has entered into an exclusive international distribution agreement with IASIS Medical for the sale of IsoRay's complete product line in Greece. IsoRay is a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung...
Invado Pharmaceuticals announced that Cleveland Clinic Cancer Clinic presented positive clinical data on NeutraSal at ONS World Congress Meeting in Washington DC. The data suggested that NeutraSal is more effective than salt and soda rinses in reducing oral toxicities in head and neck cancer patients. Pomona, NY (PRWEB) May 02, 2013 Invado Pharmaceuticals announced that Jean Hamker, RN of the Cleveland Clinic Taussig Cancer Institute presented data from a NeutraSal study at last...
Throat cancers on the rise due to epidemic of HPV infection TORONTO, April 17, 2013 /CNW/ - Researchers in London, Ontario, are conducting a first-ever clinical trial to determine which treatment option gives patients with throat cancers the best quality of life. These cancers are dramatically on the rise due to the epidemic of HPV (human papilloma virus) infection. Surgeon Dr Anthony Nichols and radiation oncologist Dr David Palma at the Lawson Research Centre have received a...
Medical centers throughout U.S. will take part in 16th Annual OHANCAW®, April 14 - 20 NEW YORK, April 10, 2013 /PRNewswire/ -- The Head and Neck Cancer Alliance (HNCA) today urged Americans to get screened for cancer by unveiling the Grand Prize winner and Runners-Up in the Oral, Head and Neck Cancer Awareness Week® (OHANCAW®) national video contest. The OHANCAW Challenge was developed to engage young adults in educating the public about the signs, symptoms and risk factors of...
Oral Cancer Screenings for the public, April 17, 2013 4:00pm-until all patients are seen. Beaumont, TX (PRWEB) April 01, 2013 Gulfside Dental is providing free visual head and neck oral cancer exams on April 17th to educate Southeast Texas on the importance of early screening and detection in oral cancers. While all Gulfside Dental patients receive visual oral cancer screenings during regular visits, April is recognized as Oral Cancer Awareness Month by the Oral Cancer Foundation and...
polyDNA will be lowering the price of Gene-Eden-VIR by 50% for those suffering from oral cancer during Oral Cancer Awareness Month. Rochester, NY (PRWEB) March 31, 2013 polyDNA is a leading developer of natural HPV remedies. As the Washington Times noted, “…(HPV) is the second leading cause of oral cancer.”[1] During the month of April, which has been sponsored by the Oral Cancer Foundation as Oral Cancer Awareness Month, polyDNA will be lowering the price of Gene-Eden-VIR, an all...
PRINCETON, N.J., March 27, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today that the Food and Drug Administration (FDA) has completed its review and cleared the Investigational New Drug (IND) application for SGX942 for the treatment of oral mucositis resulting from radiation and/or chemotherapy treatment in head and neck cancer patients. Clearance of the IND allows Soligenix to initiate a Phase...
Organization encouraging dental professionals to offer free screenings to the public NEWPORT BEACH, Calif., March 18, 2013 /PRNewswire-USNewswire/ -- What has the greatest impact on survival rates of oral cancer? Radiation? Chemotherapy? Perhaps surgery? The truth is none of these; rather, it is the point in time at which the disease is discovered. As the National Cancer Institute's SEER data clearly show, early discovery of oral cancer affects survival outcomes and reduces...
CALGARY, March 14, 2013 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2012. "We were very pleased to present our first randomized clinical data from our head and neck cancer clinical study in 2012," said Dr. Brad Thompson, President and CEO of Oncolytics. "In addition, in order to support our program, which now includes seven...
Researchers at the University of Hawai'i Cancer Center have uncovered a novel mechanism that may lead to more selective ways to stop cancer cells from spreading. Associate Professor Joe W. Ramos PhD, a cancer biologist at the UH Cancer Center and his team have identified the role of the protein RSK2 in cancer cell migration, part of the process of cancer metastasis. Cancer becomes metastatic when cells break away from the primary tumor and spread to other parts of the body. Metastatic...
